AudioScholar Dermatology Weekly (India)
AudioScholar
0
Dermatology Weekly (India) is a weekly audio briefing on the most significant peer-reviewed dermatology literature. Each episode lasts about ten minutes and is synthesized from PubMed. It is aimed at practicing physicians and is generated by AudioScholar. This edition focuses on India.
Episodes
-
First-trimester doxycycline tied to more pregnancy loss 14.11.2026 10mEditor's Pick: Doxycycline and Risk for Pregnancy Loss : A Multi-database, Multi-indication Cohort Study (Annals of Internal Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. This week: a personalised neoantigen therapy added to pembrolizumab extends recurrence-free survival in resected melanoma, first-trimester doxycycline is linked to more pregnancy loss, and an oral TYK2 and JAK1 inhibitor improves cutaneous sarcoidosi… This week's papers: 1. Intismeran Autogene plus Pembrolizumab for Resec... -
Oral povorcitinib: 75% facial repigmentation in ~19% vs 3-7% 07.11.2026 9mEditor's Pick: Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials (Nature Medicine, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic therapy for chronic inflammatory skin disease, the rising burden of bullous pemphigoid, and pediatric care alongside treatment resistance in scabies and… This week's papers: 1. Povorcitinib for nonsegmental vitiligo: two randomized, cont... -
Ruxolitinib cream for paediatric AD: no new safety signals 31.10.2026 11mEditor's Pick: 52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study (Journal of the American Academy of Dermatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning cutaneous oncology and immunotherapy, long-term management of inflammatory skin disease, and the harder edges of blistering, metabolic and genetic skin... -
HS guideline strongly backs four biologics and pain checks 24.10.2026 11mEditor's Pick: Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa (Journal of the American Academy of Dermatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning a major push in hidradenitis suppurativa, new targeted therapies and treatment selection in inflammatory skin disease, and risk stratification and staging in ski… Th... -
Lichen planus tied to higher oral and vulvar cancer rates 17.10.2026 12mEditor's Pick: Cancer Risk in Patients With Overall and Site-Specific Lichen Planus (JAMA Dermatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning cancer risk in chronic inflammatory dermatoses and melanoma diagnostics, the expanding role of JAK inhibition and phototherapy in pigmentary and sclerosing disea… This week's papers: 1. Cancer Risk in Patients With Overall and Site-Specific Lichen Planus.. JAMA Derm... -
CLIPI score predicts PFS in advanced MF/Sézary beyond stage 10.10.2026 10mEditor's Pick: Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome (JAMA Dermatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning cutaneous oncology and prevention, autoimmune blistering disease, and the expanding therapeutic toolkit for chronic inflammatory skin disease. Let's dive in. This week's papers: 1. Cutaneous Lymphoma Internation... -
Sonelokimab in HS: HiSCR75 43% vs 15%, no new safety signals 03.10.2026 10mEditor's Pick: Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA) (Journal of the American Academy of Dermatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning skin cancer and immunotherapy, immune-related toxicities, and practical consensus guidance for... -
Ruxolitinib cream improves lichen planus, no serious AEs 26.09.2026 12mEditor's Pick: Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial (JAMA Dermatology, 2026) This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice. Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning psoriasis across the lifespan, targeted small molecules moving into orphan inflammatory dermatoses, and the less glamorous but equally consequential business of… This week's papers: 1. Efficacy and Safety of Risankizumab in... -
IL-17 inhibitors for psoriasis tied to 2-4x candidiasis risk 19.09.2026 13mEditor's Pick: Risks of tuberculosis, meningitis, candidiasis, and fungal infections among patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data (British Journal of Dermatology, 2026) Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning the comparative safety and durability of biologics in inflammatory skin disease, the real-world performance of our immunomodulatory workhorses in severe and rare… This week's papers: 1. Risks of tuberculosis, meningitis, candidiasis, and fungal infections among patients receiving sys... -
Mohs in cSCC: smaller defects, no significant recurrence gap 12.09.2026 12mEditor's Pick: Five-year Recurrence Rate of Cutaneous Squamous Cell Carcinoma After Mohs Micrographic Surgery Versus Standard Excision: a Prospective Multicentre Cohort Study (British Journal of Dermatology, 2026) Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning immune-targeted therapy — where one major trial failed and several others refine how we use the drugs we already have — plus skin cancer surgery and systemic com… This week's papers: 1. Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a g... -
Recibokibart: GPP pustules clear/near-clear in ~86% vs 9% 05.09.2026 12mEditor's Pick: Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial (British Journal of Dermatology, 2026) Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning inflammatory disease therapeutics — from a new interleukin-36 antibody in pustular psoriasis to long-term JAK inhibition in eczema — plus consensus and guideline… This week's papers: 1. Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial... -
Brepocitinib tied to better dermatomyositis skin and itch 29.08.2026 12mEditor's Pick: Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial (JAMA Dermatology, 2026) Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic drug safety and the cardiometabolic interface, new targeted therapy data in inflammatory and neutrophilic skin disease, risk stratification in skin canc… This week's papers: 1. Cardiometabolic Associations of Dermatological Treatments. Part I: Systemic Therapies.. Journal of the American Academy of Dermatology 2026. 2. Cardiometa... -
HS: nearly 4 in 10 Hurley I report very severe QoL loss 22.08.2026 11mEditor's Pick: Factors influencing quality of life in hidradenitis suppurativa: Data from 1188 patients (Journal of the European Academy of Dermatology and Venereology, 2026) Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning inflammatory skin disease and its systemic burden, new mechanisms and management frameworks in atopic dermatitis and alopecia areata, and diagnostics for the con… This week's papers: 1. Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international,... -
Upadacitinib repigments ~1 in 5 with vitiligo vs 6% placebo 15.08.2026 11mEditor's Pick: Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies (The Lancet, 2026) Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning the expanding reach of oral JAK inhibitors into vitiligo and alopecia areata, safety and risk stratification at the intersection of skin disease and cancer, and… This week's papers: 1. Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of tw... -
Weekly adalimumab most cost-efficient for HS in 5 countries 08.08.2026 12mEditor's Pick: Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa (JAMA Dermatology, 2026) Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning inflammatory disease classification and the economics of biologics, real-world outcomes in atopic dermatitis and psoriasis, and a cluster of practical papers on… This week's papers: 1. Pyoderma Gangrenosum Phenotype Classification. JAMA Dermatology 2026. 2. Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa. JAMA Dermatology 2026. 3. Treatment of tinea capitis in China: a multicenter... -
This Week in Dermatology — Jul 31, 2026 01.08.2026 9mEditor's Pick: Clinical Yield of Laboratory Monitoring During Ritlecitinib Treatment for Alopecia Areata: A Prospective Real-World Cohort Study (Journal of the American Academy of Dermatology, 2026) Welcome to This Week in Dermatology. This week we are covering five notable papers spanning therapeutic advances and laboratory monitoring in alopecia areata, demographic variations in contact allergen sensitivities, multidimensional success metrics… This week's papers: 1. Clinical Yield of Laboratory Monitoring During Ritlecitinib Treatment for Alopecia Areata: A Prospective Real-World Cohort Stud... -
This Week in Dermatology — Jul 24, 2026 25.07.2026 8mEditor's Pick: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials (Nature medicine, 2026) Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic therapeutics for inflammatory skin disease, diagnostic imaging innovations, and pediatric and supportive care. Let's dive in. This week's papers: 1. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.. Nature medicine 2026. 2. Clinical and Dermoscopic Tria... -
This Week in Dermatology — Jul 17, 2026 18.07.2026 13mEditor's Pick: Cardiac structure and function in psoriasis: A cross-sectional analysis of the PSOCADIA study (Journal of the European Academy of Dermatology and Venereology, 2026) Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic manifestations and novel therapeutics in psoriasis, real-world outcomes in hair restoration, and emerging safety and diagnostic data in inflammatory der… This week's papers: 1. Efficacy and safety of inhibitory magnetic stimulation in the treatment of refractory erythema of rosacea: a prospective, randomized, controlled... -
This Week in Dermatology — Jul 10, 2026 11.07.2026 9mEditor's Pick: Recurrence of Basal Cell Carcinoma across Different Treatment Modalities: A Nationwide Study with 8 Years of Follow-up and Modelled Prediction (Acta dermato-venereologica, 2026) Welcome to This Week in Dermatology. This week we are covering ten notable papers spanning advanced management strategies for skin cancer, novel therapeutic insights in atopic dermatitis, and optimizing procedural and wound care outcomes. This week's papers: 1. Compression therapies for venous leg ulcers: The VENous Ulcer Study 6 (VenUS 6), an open, multicentre, randomised clinical trial.. PLoS medicine... -
This Week in Dermatology — Jul 3, 2026 04.07.2026 7mEditor's Pick: Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials (The British journal of dermatology, 2026) Welcome to This Week in Dermatology. This week we are covering seven notable papers spanning novel oral therapeutics for psoriasis, hair loss interventions, and complex dermatopathological entities. Let's dive in. This week's papers: 1. Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Y...
Popular in
The podcast also appears in the podcast charts of these countries.